Calcitonin use in giant cell bone tumors

Area of Science:

• Orthopedics
• Oncology
• Skeletal Biology

Background:

• Giant cell tumors express calcitonin receptors, suggesting potential therapeutic targets.
• Osteoclast activity is a hallmark of giant cell tumors.

Purpose of the Study:

• To evaluate the efficacy of salmon calcitonin as an adjuvant therapy following curettage for giant cell tumors.
• To assess the impact of calcitonin on local recurrence rates in giant cell tumors of the appendicular skeleton.

Main Methods:

• Retrospective review of 25 patients with giant cell tumors treated with curettage and salmon calcitonin.
• Follow-up duration averaged 68 months to assess local recurrence and functional outcomes using the MSTS score.

Main Results:

• A local recurrence rate of 52% was observed.
• Eight patients with recurrence achieved successful outcomes after repeat curettage and calcitonin.
• Empty cavities ossified spontaneously, with a mean MSTS score of 28.02/30.

Conclusions:

• Salmon calcitonin as an adjuvant therapy following curettage for giant cell tumors is not effective in reducing local recurrence.
• Filling agents are not necessary after curettage for giant cell tumors.